Clinical trials: Colorectal Cancer Metastatic
Metastatic Colorectal Cancer
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
The purpose of this study is to see if Panitumumab plus the other treatments will increase the time of remission. Remission means that there is no sign of the cancer.
- Trial name
- NCT01312857
- Testing
- panitumumab, Randomization to No Panitumumab
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
This phase I trial investigates the best dose, possible benefits and/or side effects of BAY 1895344 in combination with FOLFIRI in treating patients with stomach or intestinal cancer that that may have spread from where it first…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04535401
- Testing
- Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
- Where
- 10 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with a fluoropyrimidine in participants with unresectable or metastatic colorectal cancer who have not…
- Trial name
- NCT04456699
- Testing
- Olaparib, 5-FU, Bevacizumab
- Where
- 129 sites in United States, Australia and 16 more
- Volunteers
- 335 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer Metastatic, mCRC
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.
- Trial name
- NCT03563157
- Testing
- Aldoxorubicin Hydrochloride, ALT-803, ETBX-011
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- ImmunityBio, Inc.
Advanced/Metastatic Solid Tumor
KZR-261 in Subjects With Advanced Solid Malignancies
A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase…
- Trial name
- NCT05047536
- Testing
- KZR-261
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Kezar Life Sciences, Inc.
Metastatic Colorectal Cancer
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
- Trial name
- NCT00865709
- Testing
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Where
- 116 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has…
- Conditions
- Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
- Trial name
- CheckMate142 (NCT02060188)
- Testing
- Ipilimumab, Nivolumab, Cobimetinib
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 385 people
- Sponsor
- Bristol-Myers Squibb
Liver Metastases, Recurrent Colon Cancer
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
This phase II trial studies how well giving combination chemotherapy and bevacizumab before surgery and radiolabeled monoclonal antibody therapy works in treating liver metastases in patients with metastatic colorectal cancer.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer
- Trial name
- NCT01320683
- Testing
- oxaliplatin, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
RATIONALE: Thalidomide may stop the growth of colorectal cancer by stopping blood flow to the tumor. Giving thalidomide after surgery may kill any remaining tumor cells.
- Trial name
- NCT00019747
- Testing
- thalidomide, adjuvant therapy
- Where
- 6 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Metastatic Colorectal Cancer
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
This Study is in two parts, the first part is to make sure that combining a potential new treatment, cediranib (AZD2171), with a standard treatment (FOLFOX) for metastatic colorectal cancer is safe.
- Trial name
- NCT00494221
- Testing
- AZD2171, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- 2 sites in Japan
- Volunteers
- 172 people
- Sponsor
- AstraZeneca
Colonic Neoplasms
Enzastaurin for Patients With Metastatic Colorectal Cancer
Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer
- Trial name
- NCT00192114
- Testing
- Enzastaurin HCl
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Breast Neoplasms, Prostate Neoplasms
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.
- Conditions
- Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma
- Trial name
- NCT03685591
- Testing
- PF-06952229, Enzalutamide
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Pfizer
Colon Cancer Liver Metastasis
Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
The purpose of this study is to determine the safety and efficacy of Thermodox, a thermally sensitive liposomal doxorubicin, in combination with thermal ablation in the treatment of hepatic colorectal liver metastases (CRLM).
- Trial name
- ABLATE (NCT01464593)
- Testing
- Lyso-Thermosensitive Liposomal Doxorubicin, 5% Dextrose Solution, ThermoDox
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Imunon
Metastatic Colorectal Cancer
Radiosensitizing Chemotherapy withSBRT for the Treatment of Inoperable Liver and/or Lung Metastases of CRC
The purpose of this study is to study stereotactic radiotherapy with a dose of 40 Gy in 4 fractions over 2 weeks with concomitant 40 mg/m2 of irinotecan (1st and 3rd irradiation session).
- Trial name
- RSCAMPTO (NCT01220063)
- Testing
- Radiation, Irinotecan
- Where
- 6 sites in France
- Volunteers
- 47 people
- Sponsor
- Institut Cancerologie de l'Ouest
Biliary Tract Cancer (BTC), Colorectal Cancer (CRC)
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.
- Conditions
- Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC)
- Trial name
- NCT03314935
- Testing
- INCB001158, Oxaliplatin, Leucovorin
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 149 people
- Sponsor
- Incyte Corporation
Previously Untreated Metastatic Colorectal Cancer
Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.
This is an exploratory study to compare activity and safety in 400 patients with previously untreated metastatic carcinoma of the colon treated with UFOX (a combination regimen of UFT® (Tegafur plus Uracil), Oxaliplatin, Folinic…
- Trial name
- FUTURE (NCT00439517)
- Testing
- UFOX + Cetuximab, FOLFOX4 + Cetuximab
- Where
- 57 sites in Argentina, Australia and 12 more
- Volunteers
- 302 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Physician Education
A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?
Randomized trial to evaluate impact of healthcare provider( clinician and nursing staff) support and education on treatment discontinuation rates in the absence of progression in patients with metastatic colorectal cancer treated…
- Trial name
- SMART (NCT02287025)
- Testing
- Regorafenib (Stivarga, BAY73-4506), iPAD application, Bayer specialist
- Where
- 17 sites in United States
- Volunteers
- 23 people
- Sponsor
- Bayer
Metastatic Colon Cancer, Solid Tumor
Pembrolizumab + Poly-ICLC in MRP Colon Cancer
The main purpose of this study is to determine the dose of poly-ICLC that is safe and tolerable when it is combined with pembrolizumab in patients with colon cancer.
- Trial name
- NCT02834052
- Testing
- pembrolizumab, Poly-ICLC
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Asha Nayak
Metastatic Microsatellite-stable Colorectal Cancer
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
COLUMBIA-1 is a Phase 1b/2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable…
- Trial name
- NCT04068610
- Testing
- Durvalumab, Oleclumab, FOLFOX
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 61 people
- Sponsor
- MedImmune LLC
Colorectal Cancer, Liver Metastasis
Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer
Background: Some types of inflammation may increase the risk of cancers in the intestinal track. Because of this possibility, anti-inflammatory drugs may be able to prevent tumor growth and spread.
- Conditions
- Colorectal Cancer, Liver Metastasis, Colorectal Adenocarcinoma
- Trial name
- NCT01856322
- Testing
- Sulindac, Validate assays and shipping methods
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)